Quantum Biotech Early Stage: what changed
Quantum Biotech Early Stage
Largest movements
- Receivables within one year +€236,586
up €236,586 (+408%), from €57,961 to €294,547
of which Other amounts receivable: +€222,605
- Financial fixed assets +€125,000
up €125,000 (+47.7%), from €262,000 to €387,000
- Receivables after one year +€52,000
new in 2024: €52,000
- Debts after one year +€368,250
up €368,250 (+578%), from €63,750 to €432,000
- Other debts +€39,479
up €39,479 (+1,984%), from €1,990 to €41,469
- Tax, wage and social debts +€11,012
up €11,012 (+9,560%), from €115 to €11,127
- Financial charges +€20,501
up €20,501 (+56,400%), from €36 to €20,538
- Gross operating margin +€20,175
up €20,175 (+639%), from €3,159 to €23,334
- Other operating charges -€2,598
down €2,598 (-97.6%), from €2,662 to €64
Change in the result, 2023 to 2024
For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.
Derived cash bridge
The bridge is derived from the 2023 and 2024 balance sheets and the 2024 result. There is no filed cash-flow statement. You see where the money came from and where it went.
Every line side by side
| Line | Code | 2023 | 2024 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €319,962 | €738,942 | +€418,980 | +131% |
| Fixed assets | 21/28 | €262,000 | €391,120 | +€129,120 | +49.3% |
| Tangible fixed assets | 22/27 | - | €4,120 | +€4,120 | |
| Other tangible fixed assets | 26 | - | €4,120 | +€4,120 | |
| Financial fixed assets | 28 | €262,000 | €387,000 | +€125,000 | +47.7% |
| Current assets | 29/58 | €57,962 | €347,822 | +€289,861 | +500% |
| Amounts receivable after more than one year | 29 | - | €52,000 | +€52,000 | |
| Other amounts receivable | 291 | - | €52,000 | +€52,000 | |
| Amounts receivable within one year | 40/41 | €57,961 | €294,547 | +€236,586 | +408% |
| Trade receivables | 40 | €47,069 | €61,050 | +€13,981 | +29.7% |
| Other amounts receivable | 41 | €10,892 | €233,497 | +€222,605 | +2,044% |
| Cash at bank and in hand | 54/58 | €1 | €1,275 | +€1,274 | +157,336% |
| Total equity and liabilities | 10/49 | €319,962 | €738,942 | +€418,980 | +131% |
| Equity | 10/15 | €250,346 | €253,078 | +€2,733 | +1.1% |
| Contributions | 10/11 | €250,000 | €250,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €346 | €3,078 | +€2,733 | +791% |
| Amounts payable | 17/49 | €69,616 | €485,864 | +€416,248 | +598% |
| Amounts payable after more than one year | 17 | €63,750 | €432,000 | +€368,250 | +578% |
| Financial debts | 170/4 | €63,750 | €432,000 | +€368,250 | +578% |
| Amounts payable within one year | 42/48 | €5,866 | €53,864 | +€47,998 | +818% |
| Trade debts | 44 | €3,761 | €1,268 | -€2,493 | -66.3% |
| Suppliers | 440/4 | €3,761 | €1,268 | -€2,493 | -66.3% |
| Taxes, remuneration and social security | 45 | €115 | €11,127 | +€11,012 | +9,560% |
| Taxes | 450/3 | €115 | €11,127 | +€11,012 | +9,560% |
| Other amounts payable | 47/48 | €1,990 | €41,469 | +€39,479 | +1,984% |
| Other operating charges | 640/8 | €2,662 | €64 | -€2,598 | -97.6% |
| Gross operating margin | 9900 | €3,159 | €23,334 | +€20,175 | +639% |
| Operating profit (loss) | 9901 | €497 | €23,271 | +€22,773 | +4,581% |
| Financial charges | 65/66B | €36 | €20,538 | +€20,501 | +56,400% |
| Recurring financial charges | 65 | €36 | €20,538 | +€20,501 | +56,400% |
| Profit (loss) for the period before taxes | 9903 | €461 | €2,733 | +€2,272 | +493% |
| Income taxes | 67/77 | €115 | - | -€115 | |
| Profit (loss) for the period | 9904 | €346 | €2,733 | +€2,387 | +691% |
| Profit (loss) for the period to be appropriated | 9905 | €346 | €2,733 | +€2,387 | +691% |
Next steps
Calculation and sources
Source: filed annual accounts (NBB), financial years ended 31 December 2023 and 31 December 2024. Green is a favourable move for that line, red an unfavourable one. Prepared on 5 November 2026 via checked.be.